GeneDx Holdings Corp. (WGS) fair value: what the stock is really worth
As of Oct 14, 2026: fair value of GeneDx Holdings Corp. $9.62, price $68.61, upside -86.0%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range $1.24 – $411.84 · fair‑value band $6.45 – $15.40 · the $68.61 price screens above the $9.62 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow GeneDx Holdings in your weekly email
Every Wednesday you see whether GeneDx Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Show moreShow less
It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Stock analysis
GeneDx Holdings Corp. (WGS) currently trades at $68.61, while our model-based Fair Value estimate is $9.62, 86.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $15.26 per share, and 0 of the 10 models we run sit above the $68.61 price.
Bear case: the Asset-Based group reads lowest at $6.92, and 10 of the 10 models stay below the price. Data coverage for this calculation is low.
Scenario range: $6.45 (bear) to $15.40 (bull), the price of $68.61 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
GeneDx Holdings Corp. reported revenue of $428M in FY2025 versus $212M in FY2021, a compound +19.1%/yr. Reported net income was −$21.0M in FY2025.
Key figures
Market cap $2.0B · P/S ratio 4.66 · EPS (TTM) $−3.63 · Net margin −4.9% · Return on equity −40.8% · Return on assets (EBIT) −50.7% · Operating margin −15.2% · Revenue (TTM) $454M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).
What moves the price
The share trades about 59% below its 52-week high and 99% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −86%, WGS screens richer than that median.
Fair Value models
Bear$6.45Fair Value $9.62Bull$15.40
Price $68.61 · Upside -86.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+40.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−134.9% (2020) → −2.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+55.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+18.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +51.9% a year for the price and +15.8% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (75 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 127 stocks
Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−86.0% · Bottom 25%
Profitability
Return on assets−3.7% · Below median
Net margin (12 months)−23.4% · Bottom 25%
Operating margin (12 months)−15.2% · Bottom 25%
Growth and dividend
Revenue growth11.4% · Above median
Balance sheet
Debt / equity0.16× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B6.61× · Priciest 25%
P/S (12 months)4.49× · Pricier than median
Price / free cash flow142.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)57· sector 22
PAST (return on equity)0· sector 13
HEALTH (low debt)92· sector 93
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is GeneDx Holdings Corp. (WGS) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of $9.62 versus a price of $68.61, about −86% upside (overvalued).
What is the fair value of WGS?
Our model-based fair value for GeneDx Holdings Corp. is $9.62 (as of Oct 2, 2026), built from audited fundamentals. The current price: $68.61.
What is the quality score of WGS?
GeneDx Holdings Corp. has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GeneDx Holdings Corp. (WGS)?
Our model-based price target is the fair value of $9.62 (as of Oct 2, 2026) from 10 valuation models. Cautious scenario $6.45, optimistic scenario $15.40. It is a calculation from audited fundamentals, not an analyst target.
What is the GeneDx Holdings Corp. stock forecast for 2026?
Our models put fair value at $9.62, about −86% upside versus a price of $68.61 (overvalued). Cautious scenario $6.45, optimistic scenario $15.40. The calculation is refreshed regularly with new filings.
What is the revenue of GeneDx Holdings Corp. (WGS)?
GeneDx Holdings Corp. reported trailing-twelve-month revenue of about $454M (latest available figure, as of Oct 2, 2026).
What growth is priced into GeneDx Holdings Corp. (WGS)?
For today's price to be fair in a discounted-cash-flow model, GeneDx Holdings Corp. would have to grow free cash flow by +55.5 % per year for five years (discount rate 12.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.0 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of WGS use?
Our models discount GeneDx Holdings Corp. at 12.2 %: a base by market capitalisation (mid), damped by beta 2.01, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For GeneDx Holdings Corp. that is +55.5 % per year a year over ten years, using the same discount rate (12.2 %) and the same formula as our fair value.
How much growth has GeneDx Holdings Corp. (WGS) delivered so far?
Over the past 5 years revenue at GeneDx Holdings Corp. grew +19.0 % a year. The price currently implies +55.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of GeneDx Holdings Corp. (WGS) growing?
The median revenue growth in the sector is +5.5 % a year. That is the yardstick for the growth priced into GeneDx Holdings Corp. (+55.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of GeneDx Holdings Corp. (WGS)?
The free-cash-flow yield on the price is 0.70 %: that much free cash flow GeneDx Holdings Corp. produces per unit of market value. When it exceeds the discount rate of our models (12.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of GeneDx Holdings Corp. (WGS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GeneDx Holdings Corp. it is $9.62 per share (as of Oct 2, 2026), against a price of $68.61. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is GeneDx Holdings Corp. stock overvalued or undervalued in 2026?
As of Oct 2, 2026, WGS trades above its calculated fair value: price $68.61, fair value $9.62, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of WGS?
No. The price is what the market pays today ($68.61); the fair value is what the company's own numbers justify ($9.62). For GeneDx Holdings Corp. the two are $58.99 per share apart. That gap is exactly why we show both numbers side by side.
How much is GeneDx Holdings Corp. worth?
The market values GeneDx Holdings Corp. at about $2.0B (market capitalisation, as of Oct 2, 2026). Per share that is $68.61; our models calculate a fair value of $9.62 per share.
What do the bullish and bearish scenarios say about WGS?
Our models span a range for GeneDx Holdings Corp.: cautious scenario $6.45, base $9.62, optimistic $15.40 per share (as of Oct 2, 2026, price $68.61). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of GeneDx Holdings Corp. (WGS)?
Balance-sheet figures for GeneDx Holdings Corp. (as of Oct 2, 2026): return on equity −40.8%, debt of 0.16 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is WGS from its 52-week high?
GeneDx Holdings Corp. trades at $68.61, about 59% below its 52-week high of $167.52 and 99% above the low of $34.51 (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of $9.62 is for.
Which stocks are comparable to GeneDx Holdings Corp.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GeneDx Holdings Corp. stock attractive at the current price?
The data as of Oct 2, 2026: price $68.61, calculated fair value $9.62 (−86%), Quality Score 48/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of WGS calculated?
We run GeneDx Holdings Corp. through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $9.62, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.5 % above its aggregate fair value. GeneDx Holdings Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GeneDx Holdings Corp. (WGS)?
The closing price on Oct 14, 2026 was $68.61. Our model-based fair value is $9.62, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GeneDx Holdings Corp. right now?
The price sits above even our optimistic bull case ($15.40). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($6.45 to $15.40) leaves room in how you read the outcome.
Key figures of GeneDx Holdings Corp.
How large is the market capitalisation of GeneDx Holdings Corp. (WGS)?
The market capitalisation of GeneDx Holdings Corp. is $2.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GeneDx Holdings Corp. (WGS)?
The price-to-sales ratio of GeneDx Holdings Corp. is 4.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GeneDx Holdings Corp. (WGS)?
Earnings per share at GeneDx Holdings Corp. are $−3.63. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of GeneDx Holdings Corp. (WGS)?
The net margin of GeneDx Holdings Corp. is −4.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GeneDx Holdings Corp. (WGS)?
The return on equity (ROE) of GeneDx Holdings Corp. is −40.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GeneDx Holdings Corp. (WGS)?
On an EBIT basis the return on assets of GeneDx Holdings Corp. is −50.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GeneDx Holdings Corp. (WGS)?
The operating margin of GeneDx Holdings Corp. is −15.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GeneDx Holdings Corp. (WGS)?
Revenue at GeneDx Holdings Corp. is growing +11.4% versus a year earlier (3y avg +22.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does GeneDx Holdings Corp. (WGS) carry?
The net debt of GeneDx Holdings Corp. is $46.9M (fiscal year 2025, ≈ 3.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch GeneDx Holdings Corp. in the live analysis
One click puts GeneDx Holdings Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 2, 2026